Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Más filtros











Intervalo de año de publicación
1.
Haematologica ; 103(9): 1557-1567, 2018 09.
Artículo en Inglés | MEDLINE | ID: mdl-29880611

RESUMEN

Severe thrombocytopenia (≤50×109 platelets/L) due to hematological malignancy and intensive chemotherapy is associated with an increased risk of clinically significant bleeding. Since the bleeding risk is not linked to the platelet count only, other hemostatic factors must be involved. We studied platelet function in 77 patients with acute leukemia, multiple myeloma or malignant lymphoma, who experienced chemotherapy-induced thrombocytopenia. Platelets from all patients - independent of disease or treatment type - were to a variable extent compromised in Ca2+ flux, integrin a ß activation and P-selectin expression when stimulated with a panelIIbof3 agonists. The patients' platelets were also impaired in spreading on fibrinogen. Whereas the Ca2+ store content was unaffected, the patients' platelets showed ongoing phosphatidylserine exposure, which was not due to apoptotic caspase activity. Interestingly, mitochondrial function was markedly reduced in platelets from a representative subset of patients, as evidenced by a low mitochondrial membrane potential (P<0.001) and low oxygen consumption (P<0.05), while the mitochondrial content was normal. Moreover, the mitochondrial impairments coincided with elevated levels of reactive oxygen species (Spearman's rho=-0.459, P=0.012). Markedly, the impairment of platelet function only appeared after two days of chemotherapy, suggesting origination in the megakaryocytes. In patients with bone marrow recovery, platelet function improved. In conclusion, our findings disclose defective receptor signaling related to impaired mitochondrial bioenergetics, independent of apoptosis, in platelets from cancer patients treated with chemotherapy, explaining the low hemostatic potential of these patients.


Asunto(s)
Plaquetas/efectos de los fármacos , Plaquetas/metabolismo , Mitocondrias/efectos de los fármacos , Mitocondrias/metabolismo , Neoplasias/complicaciones , Trombocitopenia/etiología , Trombocitopenia/metabolismo , Adulto , Anciano , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Apoptosis/efectos de los fármacos , Biomarcadores , Coagulación Sanguínea/efectos de los fármacos , Señalización del Calcio/efectos de los fármacos , Estudios de Casos y Controles , Femenino , Humanos , Masculino , Persona de Mediana Edad , Neoplasias/sangre , Neoplasias/tratamiento farmacológico , Activación Plaquetaria/efectos de los fármacos , Agregación Plaquetaria/efectos de los fármacos , Recuento de Plaquetas , Pruebas de Función Plaquetaria , Índice de Severidad de la Enfermedad , Trombocitopenia/sangre , Trombocitopenia/diagnóstico
2.
Sci Rep ; 6: 34440, 2016 10 03.
Artículo en Inglés | MEDLINE | ID: mdl-27694929

RESUMEN

The mechanisms protecting from immunopathology during acute bacterial infections are incompletely known. We found that in response to apoptotic immune cells and live or dead Listeria monocytogenes scavenger receptor BI (SR-BI), an anti-atherogenic lipid exchange mediator, activated internalization mechanisms with characteristics of macropinocytosis and, assisted by Golgi fragmentation, initiated autophagic responses. This was supported by scavenger receptor-induced local increases in membrane cholesterol concentrations which generated lipid domains particularly in cell extensions and the Golgi. SR-BI was a key driver of beclin-1-dependent autophagy during acute bacterial infection of the liver and spleen. Autophagy regulated tissue infiltration of neutrophils, suppressed accumulation of Ly6C+ (inflammatory) macrophages, and prevented hepatocyte necrosis in the core of infectious foci. Perifocal levels of Ly6C+ macrophages and Ly6C- macrophages were unaffected, indicating predominant regulation of the focus core. SR-BI-triggered autophagy promoted co-elimination of apoptotic immune cells and dead bacteria but barely influenced bacterial sequestration and survival or inflammasome activation, thus exclusively counteracting damage inflicted by immune responses. Hence, SR-BI- and autophagy promote a surveillance pathway that partially responds to products of antimicrobial defenses and selectively prevents immunity-induced damage during acute infection. Our findings suggest that control of infection-associated immunopathology can be based on a unified defense operation.


Asunto(s)
Autofagia/inmunología , Macrófagos/inmunología , Microdominios de Membrana/inmunología , Pinocitosis/inmunología , Receptores Depuradores de Clase B/inmunología , Animales , Autofagia/genética , Beclina-1/genética , Beclina-1/inmunología , Aparato de Golgi/genética , Aparato de Golgi/inmunología , Listeria monocytogenes/inmunología , Listeriosis/genética , Listeriosis/inmunología , Listeriosis/patología , Hepatopatías/genética , Hepatopatías/inmunología , Hepatopatías/patología , Macrófagos/patología , Microdominios de Membrana/genética , Ratones , Ratones Noqueados , Infiltración Neutrófila/genética , Infiltración Neutrófila/inmunología , Neutrófilos/inmunología , Neutrófilos/patología , Pinocitosis/genética , Receptores Depuradores de Clase B/genética , Enfermedades del Bazo/genética , Enfermedades del Bazo/inmunología , Enfermedades del Bazo/patología
3.
Lasers Surg Med ; 43(6): 522-7, 2011 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-21761423

RESUMEN

BACKGROUND AND OBJECTIVE: The excimer laser-assisted non-occlusive anastomosis (ELANA) technique is a way of making an anastomosis of vessels without temporal occlusion that is used for cerebral revascularization. Currently, 10 mJ of laser energy is used during the ELANA procedure. We have recently demonstrated that increasing the laser energy may increase flap retrieval rate. The aim of the present study was to study the acute effect of increased laser energy during the ELANA procedure on the recipient vessel wall. MATERIALS AND METHODS: The ELANA technique was performed on the abdominal aortas of rabbits under anesthesia using three categories of laser energy (two laser episodes of 10, 13, and 15 mJ, respectively). The rabbits were subsequently sacrificed and the anastomoses were removed. A non-lased rabbit aorta was used as control. Recipient arteries were studied using histopathology and transmission electron microscopy. RESULTS: In all three categories of laser energy and in the control group, the tunica media and adventitia adjacent to the anastomosis were intact, apart from damage caused by sutures. In the control group, the endothelium was fully intact. In the 10 and 13 mJ subgroups, the endothelium was mostly intact [92% (range 85-98) and 87% (range 80-90) for 10 and 13 mJ, respectively]. In the 15 mJ subgroup, most of the endothelium was absent [32% (range 20-40) of endothelium intact], predominantly at the side opposed to the anastomosis. CONCLUSION: Increasing the laser energy during the ELANA procedure from 10 to 13 mJ does not cause additional acute damage to the vessel wall. Increasing the laser energy from 13 to 15 mJ results in increased acute damage of the endothelium, whereas tunica media and adventitia remain unaffected. Further studies are required to assess the long-term effects of increased laser energy during the ELANA technique.


Asunto(s)
Arterias/patología , Arterias/cirugía , Láseres de Excímeros/uso terapéutico , Procedimientos Quirúrgicos Vasculares/métodos , Anastomosis Quirúrgica/métodos , Animales , Aorta Torácica/patología , Aorta Torácica/cirugía , Conejos
4.
Thromb Haemost ; 99(6): 1068-78, 2008 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-18521510

RESUMEN

Several studies have highlighted a specific role for membrane cholesterol domains in platelet signalling. Upon adhesion to von Willebrand factor (VWF) or collagen, cholesterol-rich domains (CRDs) accumulate in filopodial extensions and selectively harbour counterpart receptors (GPIb and GPVI) and associated signalling molecules. In the present study we have addressed the role of membrane cholesterol in Ca(2+) signalling and secretion during the interaction of platelets with VWF and collagen. VWF/ristocetin-induced platelet aggregation was delayed after treatment with methyl beta-cyclodextrin (mbCD), but the maximal aggregation response was not affected. Platelet spreading but not adhesion to immobilised VWF under flow was attenuated by cholesterol removal, and accompanied by moderate lowering in the spiking Ca(2+) response. On the other hand, platelet interaction with collagen was quite sensitive to cholesterol depletion. Platelet aggregation decreased after treatment with mbCD, and Ca(2+) responses were decreased, both under static and flow conditions. Cholesterol depletion affected the secondary feedback activation via release of thromboxane A(2) and ADP. The collagen-induced secretion of alpha granules and surface translocation of P-selectin and CD63 was also critically affected by cholesterol depletion. Confocal microscopy showed localization of p-Tyr at sites of contact with substrate and other platelets, where also CRDs accumulate. Our data thus reveal a more critical role for membrane cholesterol in collagen-induced than in VWF-induced Ca(2+) signalling, and furthermore support the concept that secondary activation responses are dependent on intact CRDs.


Asunto(s)
Plaquetas/metabolismo , Señalización del Calcio , Membrana Celular/metabolismo , Colesterol/metabolismo , Colágeno Tipo III/metabolismo , Factor de von Willebrand/metabolismo , Adenosina Difosfato/metabolismo , Antígenos CD/metabolismo , Comunicación Autocrina , Plaquetas/efectos de los fármacos , Plaquetas/inmunología , Señalización del Calcio/efectos de los fármacos , Membrana Celular/efectos de los fármacos , Membrana Celular/inmunología , Colesterol/deficiencia , Hemorreología , Humanos , Microscopía Confocal , Selectina-P/metabolismo , Fosforilación , Adhesividad Plaquetaria , Agregación Plaquetaria , Glicoproteínas de Membrana Plaquetaria/metabolismo , Transporte de Proteínas , Receptores de Colágeno/metabolismo , Vesículas Secretoras/metabolismo , Estrés Mecánico , Tetraspanina 30 , Tromboxano A2/metabolismo , Factores de Tiempo , Tirosina/metabolismo , beta-Ciclodextrinas/farmacología
5.
Proc Natl Acad Sci U S A ; 103(19): 7420-5, 2006 May 09.
Artículo en Inglés | MEDLINE | ID: mdl-16648260

RESUMEN

S-nitrosylation, the selective modification of cysteine residues in proteins to form S-nitrosocysteine, is a major emerging mechanism by which nitric oxide acts as a signaling molecule. Even though nitric oxide is intimately involved in the regulation of vascular smooth muscle cell functions, the potential protein targets for nitric oxide modification as well as structural features that underlie the specificity of protein S-nitrosocysteine formation in these cells remain unknown. Therefore, we used a proteomic approach using selective peptide capturing and site-specific adduct mapping to identify the targets of S-nitrosylation in human aortic smooth muscle cells upon exposure to S-nitrosocysteine and propylamine propylamine NONOate. This strategy identified 20 unique S-nitrosocysteine-containing peptides belonging to 18 proteins including cytoskeletal proteins, chaperones, proteins of the translational machinery, vesicular transport, and signaling. Sequence analysis of the S-nitrosocysteine-containing peptides revealed the presence of acid/base motifs, as well as hydrophobic motifs surrounding the identified cysteine residues. High-resolution immunogold electron microscopy supported the cellular localization of several of these proteins. Interestingly, seven of the 18 proteins identified are localized within the ER/Golgi complex, suggesting a role for S-nitrosylation in membrane trafficking and ER stress response in vascular smooth muscle.


Asunto(s)
Cisteína/análogos & derivados , Células Musculares/metabolismo , Músculo Liso Vascular/metabolismo , Nitrógeno/química , Proteoma/química , Proteoma/metabolismo , S-Nitrosotioles/química , S-Nitrosotioles/metabolismo , Secuencia de Aminoácidos , Células Cultivadas , Cisteína/química , Cisteína/metabolismo , Humanos , Espectrometría de Masas , Microscopía Electrónica de Transmisión , Microscopía Inmunoelectrónica , Datos de Secuencia Molecular , Células Musculares/química , Músculo Liso Vascular/química , Nitrógeno/metabolismo , Péptidos/química
6.
J Histochem Cytochem ; 52(10): 1277-85, 2004 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-15385574

RESUMEN

Localization and coordinate phosphorylation/dephosphorylation of endothelial nitric oxide synthase (eNOS) are critical determinants for the basal and stimulated production of nitric oxide. Several phosphorylation sites in eNOS have been identified as targets of the cAMP-dependent protein kinase A (PKA). Basal eNOS activity is also regulated by interaction with caveolin-1, the major coat protein of caveolae. In the present study we have examined in rat aorta endothelium the subcellular steady-state distribution of eNOS, the catalytic subunit of PKA (PKA-c), and caveolin-1. Basal eNOS expression was found in two distinct locations, the endothelial cell surface and the Golgi complex. Cell surface eNOS was equally distributed over caveolar and non-caveolar membranes but was 2.5-fold enriched on luminal lamellipodia located at endothelial cell contacts. PKA-c colocalized with eNOS in the lamellipodia, whereas caveolin-1 was absent from these membrane domains. PKA-c was also found associated with cell surface caveolae and with tubulovesicular membranes of Golgi complex and endosomes. The topological proximity of eNOS with the catalytic subunit of PKA in restricted intracellular locations may provide mechanisms for differential PKA-mediated eNOS regulation.


Asunto(s)
Proteínas Quinasas Dependientes de AMP Cíclico/metabolismo , Endotelio Vascular/enzimología , Uniones Intercelulares/enzimología , Óxido Nítrico Sintasa/metabolismo , Óxido Nítrico/biosíntesis , Animales , Aorta/enzimología , Dominio Catalítico , Caveolas/enzimología , Caveolina 1 , Caveolinas/metabolismo , Células Cultivadas , Endotelio Vascular/ultraestructura , Técnica del Anticuerpo Fluorescente , Aparato de Golgi/enzimología , Microscopía Inmunoelectrónica , Óxido Nítrico Sintasa de Tipo III , Ratas
7.
Blood ; 103(5): 1720-7, 2004 Mar 01.
Artículo en Inglés | MEDLINE | ID: mdl-14592825

RESUMEN

Recombinant factor VIIa (rFVIIa) is a safe and effective prohemostatic drug for patients with Glanzmann thrombasthenia (GT). However, the mechanism of action of rFVIIa in these patients is still unclear. Although patients with GT are characterized by a complete absence of platelet aggregation to a variety of agonists, it has been shown that GT platelets are able to form aggregates, provided polymerizing fibrin is present. We studied the effect of rFVIIa-mediated fibrin formation on aggregation of alphaIIbbeta3-deficient platelets. When washed platelets from GT patients or platelets from healthy volunteers treated with an arginyl-glycyl-aspartyl-containing peptide were activated with collagen in the presence of rFVIIa and purified coagulation factors X, II, and fibrinogen, complete aggregation occurred after a lag phase. Fibrin generation proceeded via rFVIIa-mediated thrombin generation on the activated platelet surface independently of tissue factor. Electron microscopic analysis of alphaIIbbeta3-independent platelet aggregates showed a densely packed structure suggestive of a true platelet-fibrin interaction and not via trapping of platelets into a fibrin network. Also, rFVIIa-mediated alphaIIbbeta3-independent aggregation was demonstrated under conditions of flow using a collagen-coated surface. In conclusion, the efficacy of rFVIIa in GT patients might be explained by induction of alphaIIbbeta3-independent platelet aggregation, which compensates the lack of alphaIIbbeta3-dependent aggregation.


Asunto(s)
Plaquetas/metabolismo , Factor VIIa/fisiología , Fibrina/metabolismo , Complejo GPIIb-IIIa de Glicoproteína Plaquetaria/fisiología , Proteínas Recombinantes/metabolismo , Tromboplastina/metabolismo , Colágeno/metabolismo , Factor X/metabolismo , Fibrina/química , Fibrinógeno/metabolismo , Humanos , Microscopía Electrónica , Péptidos/química , Perfusión , Agregación Plaquetaria , Protrombina/metabolismo , Receptor PAR-1/metabolismo , Trombastenia/sangre , Trombina/metabolismo , Factores de Tiempo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA